title: Pemetrexed approved for the first-line treatment of non-small-cell lung cancer: summary of the NICE appraisal.
authors.forename: Panagiota
authors.initials: P
authors.lastname: Vrouchou
authors.forename: Prashanth
authors.initials: P
authors.lastname: Kandaswamy
authors.forename: Elisabeth
authors.initials: E
authors.lastname: George
authors.forename: David
authors.initials: D
authors.lastname: Barnett
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000191:economics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000191:economics; D002945:Cisplatin / Q000008:administration & dosage; D003362:Cost-Benefit Analysis; D017277:Drug Approval; D016527:Drug Costs; D005971:Glutamates / Q000008:administration & dosage* / Q000191:economics; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000191:economics; D000068437:Pemetrexed; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D000964:Antimetabolites, Antineoplastic; D005971:Glutamates; D000068437:Pemetrexed; D006147:Guanine; D002945:Cisplatin